FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the application of a biologically active peptide which represents the amino acid sequence SEQ ID No.1.
EFFECT: preparation of a drug for modulation of at least one of the following conditions: fatigue, liver glycogen level and blood lactic acid level.
30 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOLOGICALLY ACTIVE DERIVATIVES OF PEPTIDE VAPEEHPTLLTEAPLNPK | 2005 |
|
RU2377249C2 |
| RECOVERED PEPTIDE STIMULATING ANTITUMOUR IMMUNE RESPONSE, BASED PHARMACEUTICAL COMPOSITION, METHOD OF TREATING MAMMAL AND METHOD OF IMMUNE RESPONSE MODULATION | 2002 |
|
RU2425053C2 |
| PEPTIDE STIMULATING ANTITUMOR IMMUNE RESPONSE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD FOR TREATMENT OF MAMMAL AND METHOD FOR MODULATION OF IMMUNE RESPONSE | 2002 |
|
RU2305107C2 |
| NEW ANTIBODY TO TSLP-RECEPTOR OF HUMAN | 2014 |
|
RU2689528C2 |
| NEW LUCIFERASES AND METHODS OF THEIR USE | 2017 |
|
RU2674894C2 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2644678C1 |
| NEW VERSION OF EXENDIN OR ITS CONJUGATE | 2010 |
|
RU2528734C2 |
| NEW ANTI-DR5 ANTIBODY | 2011 |
|
RU2590711C2 |
| THYMUS-SPECIFIC PROTEIN | 2005 |
|
RU2535971C2 |
